Miriam Angeloni

Mrs. Miriam Angeloni

Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Germany
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2024 in Histopathology
Verified
Journal Article
Open access
VWVeronika Weyerer
Veronika Weyerer
ABAnnalena Branz
Annalena Branz
PSPamela L Strissel
Pamela L Strissel
RSReiner Strick
Reiner Strick
FLFabienne Lange
Fabienne Lange
MEMarkus Eckstein
Markus Eckstein
Aims: Treatment options for advanced urothelial carcinoma (aUC) rapidly evolved: besides immunomodulative therapeutic options and inhibitors targeting Fibroblast growth factor receptor (FGFR) alterations, two new antibody‐drug conjugates (ADC), sacituzumab govitecan (SG) and enfortumab vedotin (EV), have been approved. However, little is known about the associations of specific aUC properties and the surface target expression of TROP2 and NECTIN‐4. Our aim was to characterize associations of TACSTD2/TROP2 and NECTIN‐4/NECTIN‐4 protein and gene expression with morphomolecular and clinicopathological characteristics of aUC in two large independent cohorts.Methods and results: The TCGA BLCA (n = 405) and the CCC‐EMN (n = 247) cohorts were retrospectively analysed. TROP2/TACSTD2 and NECTIN‐4/NECTIN‐4 are highly expressed at the protein and transcript level in aUC, and their expression status did not correlate with patient survival in both cohorts. NECTIN‐4/NECTIN‐4 expression was higher in luminal tumours and reduced in squamous aUCs. NECTIN‐4 was negative in 10.6% of samples, and 18.4% of samples had low expression (H‐score <15). The TROP2 negativity rate amounted to 6.5%. TACSTD2 and NECTIN‐4 expression was reduced in neuroendocrine‐like and/or protein‐based double‐negative tumours. TROP2‐ and NECTIN‐4‐negative tumours included one sarcomatoid and four neuroendocrine aUC. FGFR3 alterations and PD‐L1 expression on tumour and immune cells did not associate with TROP2 or NECTIN‐4 expression.Conclusions: TACSTD2/TROP2 and NECTIN‐4/NECTIN‐4 are widely expressed in aUC, independent of FGFR3 alterations or PD‐L1 expression, thus representing a suitable target for ADC treatment in the majority of aUC. The expression loss was associated with aggressive morphomolecular aUC subtypes, i.e. neuroendocrine(‐like) and sarcomatoid aUC.

Verified
Journal Article
Open access
PDF file
RERamona Erber
Ramona Erber
Miriam AngeloniMiriam Angeloni
Miriam Angeloni
Robert StoehrRobert Stoehr
Robert Stoehr
MLMichael Patrick Lux
Michael Patrick Lux
DUDaniel Ulbrich-Gebauer
Daniel Ulbrich-Gebauer
Arndt HartmannArndt Hartmann
Arndt Hartmann
In intermediate risk hormone receptor (HR) positive, HER2 negative breast cancer (BC), the decision regarding adjuvant chemotherapy might be facilitated by multigene expression tests. In all, 142 intermediate risk BCs were investigated using the PAM50-based multigene expression test Prosigna® in a prospective multicentric study. In 119/142 cases, Prosigna® molecular subtyping was compared with local and two central (C1 and C6) molecular-like subtypes relying on both immunohistochemistry (IHC; HRs, HER2, Ki-67) and IHC + tumor grade (IHC+G) subtyping. According to local IHC, 35.4% were Luminal A-like and 64.6% Luminal B-like subtypes (local IHC+G subtype: 31.9% Luminal A-like; 68.1% Luminal B-like). In contrast to local and C1 subtyping, C6 classified >2/3 of cases as Luminal A-like. Pairwise agreement between Prosigna® subtyping and molecular-like subtypes was fair to moderate depending on molecular-like subtyping method and center. The best agreement was observed between Prosigna® (53.8% Luminal A; 44.5% Luminal B) and C1 surrogate subtyping (Cohen’s kappa = 0.455). Adjuvant chemotherapy was suggested to 44.2% and 88.6% of Prosigna® Luminal A and Luminal B cases, respectively. Out of all Luminal A-like cases (locally IHC/IHC+G subtyping), adjuvant chemotherapy was recommended if Prosigna® testing classified as Prosigna® Luminal A at high / intermediate risk or upgraded to Prosigna® Luminal B.

Verified
Journal Article
Open access
PDF file
SKStefanie A. Köhler
Stefanie A. Köhler
LBLisa Brandl
Lisa Brandl
PSPamela L. Strissel
Pamela L. Strissel
LGLaura Gloßner
Laura Gloßner
AEArif B. Ekici
Arif B. Ekici
RSReiner Strick
Reiner Strick
Methylene blue (MB) is a dye used for histology with clinical importance and intercalates into nucleic acids. After MB staining of formalin fixed paraffin embedded (FFPE) muscle invasive bladder cancer (MIBC) and normal urothelium, specific regions could be microdissected. It is not known if MB influences RNA used for gene expression studies. Therefore, we analyzed MIBC using five different RNA isolation methods comparing patient matched FFPE and fresh frozen (FF) tissues pre-stained with or without MB. We demonstrate a positive impact of MB on RNA integrity with FF tissues using real time PCR with no interference of its chemical properties. FFPE tissues showed no improvement of RNA integrity, which we propose is due to formalin induced nucleotide crosslinks. Using direct multiplex RNA hybridization the best genes for normalization of MIBC and control tissues were identified from 34 reference genes. In addition, 5SrRNA and 5.8SrRNA were distinctive reference genes detecting <200 bp fragments important for mRNA analyses. Using these normalized RNAs from MB stained MIBC and applying multiplex RNA hybridization and mRNA sequencing, a minimal gene expression panel precisely identified luminal and basal MIBC tumor subtypes, important for diagnosis, prognosis and chemotherapy response.

5 January 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
SBSimone Bertz
Simone Bertz
Miriam AngeloniMiriam Angeloni
Miriam Angeloni
JDJan Drgac
Jan Drgac
CFChristina Falkeis
Christina Falkeis
CLCorinna Lang-Schwarz
Corinna Lang-Schwarz
MVMichael Vieth
Michael Vieth
Background: We aimed to provide insight into the actual frequencies of gastric adenoma types and their association with gastritis status and associated mucosal changes with a focus on Helicobacter infection and the operative link on gastritis assessment (OLGA)/operative link on gastric intestinal metaplasia assessment (OLGIM) staging. Methods: From the archive of the Institute of Pathology in Bayreuth, we collected a consecutive series of 1058 gastric adenomas diagnosed between 1987 and 2017. Clinicopathological parameters retrieved from diagnostic reports included adenoma type and localization, associated mucosal changes in antrum and corpus (i.e., type of gastritis, the extent of intestinal metaplasia and atrophy), gender, date of birth, and date of diagnosis. Results: Intestinal-type adenoma was the most frequent adenoma (89.1%), followed by foveolar-type adenoma (4.3%), pyloric gland adenoma (3.4%), adenomas associated with hereditary tumor syndromes (2.8%), and oxyntic gland adenoma (0.4%). Adenomas were found in the background of Helicobacter pylori (H. pylori) gastritis in 23.9%, Ex-H. pylori gastritis in 36.0%, autoimmune gastritis in 24.8%, chemical reactive gastritis in 7.4%, and others in 0.1%. More than 70% of patients with gastric adenomas had low-risk stages in OLGA and OLGIM. Conclusions: We found a higher frequency of foveolar-type adenoma than anticipated from the literature. It needs to be questioned whether OLGA/OLGIM staging can be applied to all patients.

19 March 2024 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
PDF file
Miriam AngeloniMiriam Angeloni
Miriam Angeloni
TDThomas van Doeveren
Thomas van Doeveren
SLSebastian Lindner
Sebastian Lindner
PVPatrick Volland
Patrick Volland
JSJorina Schmelmer
Jorina Schmelmer
VBVeronika Bahlinger
Veronika Bahlinger
Upper tract urothelial carcinoma (UTUC) is a rare and aggressive, yet understudied, urothelial carcinoma (UC). The more frequent UC of the bladder comprises several molecular subtypes, associated with different targeted therapies and overlapping with protein‐based subtypes. However, if and how these findings extend to UTUC remains unclear. Artificial intelligence‐based approaches could help elucidate UTUC's biology and extend access to targeted treatments to a wider patient audience. Here, UTUC protein‐based subtypes were identified, and a deep‐learning (DL) workflow was developed to predict them directly from routine histopathological H&E slides. Protein‐based subtypes in a retrospective cohort of 163 invasive tumors were assigned by hierarchical clustering of the immunohistochemical expression of three luminal (FOXA1, GATA3, and CK20) and three basal (CD44, CK5, and CK14) markers. Cluster analysis identified distinctive luminal (N = 80) and basal (N = 42) subtypes. The luminal subtype mostly included pushing, papillary tumors, whereas the basal subtype diffusely infiltrating, non‐papillary tumors. DL model building relied on a transfer‐learning approach by fine‐tuning a pre‐trained ResNet50. Classification performance was measured via three‐fold repeated cross‐validation. A mean area under the receiver operating characteristic curve of 0.83 (95% CI: 0.67–0.99), 0.8 (95% CI: 0.62–0.99), and 0.81 (95% CI: 0.65–0.96) was reached in the three repetitions. High‐confidence DL‐based predicted subtypes showed significant associations (p < 0.001) with morphological features, i.e. tumor type, histological subtypes, and infiltration type. Furthermore, a significant association was found with programmed cell death ligand 1 (PD‐L1) combined positive score (p < 0.001) and FGFR3 mutational status (p = 0.002), with high‐confidence basal predictions containing a higher proportion of PD‐L1 positive samples and high‐confidence luminal predictions a higher proportion of FGFR3‐mutated samples. Testing of the DL model on an independent cohort highlighted the importance to accommodate histological subtypes. Taken together, our DL workflow can predict protein‐based UTUC subtypes, associated with the presence of targetable alterations, directly from H&E slides.

22 June 2023 in medRxiv
Verified
Preprint
Open access
PDF file
Miriam AngeloniMiriam Angeloni
Miriam Angeloni
TDThomas van Doeveren
Thomas van Doeveren
SLSebastian Lindner
Sebastian Lindner
PVPatrick Volland
Patrick Volland
JSJorina Schmelmer
Jorina Schmelmer
VBVeronika Bahlinger
Veronika Bahlinger
Background: Urothelial carcinoma of the bladder (UBC) comprises several molecular subtypes, which are associated with different targetable therapeutic options. However, if and how these associations extend to the rare upper tract urothelial carcinoma (UTUC) remains unclear. Objective: Identifying UTUC protein-based subtypes and developing a deep-learning (DL) workflow to predict these subtypes directly from histopathological H&E slides. Design, Setting, and Participants: Subtypes in a retrospective cohort of 163 invasive samples were assigned on the basis of the immunohistochemical expression of three luminal (FOXA1, GATA3, CK20) and three basal (CD44, CK5, CK14) markers. DL model building relied on a transfer-learning approach. Outcome Measurements and Statistical Analysis: Classification performance was measured via repeated cross-validation, including assessment of the area under the receiver operating characteristic (AUROC). The association of the predicted subtypes with histological features, PD-L1 status, and FGFR3 mutation was investigated. Results and Limitations: Distinctive luminal and basal subtypes were identified and could be successfully predicted by the DL (AUROC 95 th CI: 0.62-0.99). Predictions showed morphology as well as presence of FGFR3 -mutations and PD-L1 positivity that were consistent with the predicted subtype. Testing of the DL model on an independent cohort highlighted the importance to accommodate histological subtypes. Conclusions: Our DL workflow is able to predict protein-based UTUC subtypes directly from H&E slides. Furthermore, the predicted subtypes associate with the presence of targetable genetic alterations. Patient Summary: UTUC is an aggressive, yet understudied, disease. Here, we present an artificial intelligence algorithm that can predict UTUC subtypes directly from routine histopathological slides and support the identification of patients that may benefit from targeted therapy.